Role of Radiation Therapy in Younger and Older Adults with Primary Mediastinal Large B Cell Lymphoma in Rituximab Era: A U.S. Population-Based Analysis.

Abstract

The role of mediastinal radiotherapy (RT) in primary mediastinal large B cell lymphoma is controversial. We used the Surveillance, Epidemiology and End Results program 18 database to identify the role after rituximab approval. Among 474 patients included, 65.8% were 18-39 years old and 34.2% were 40-59 years old; 45.8% received RT. Univariate analysis showed that disease stage and race could affect survival. After adjusting for stage and race, RT was correlated with prognosis in patients aged 40-59 years (none/unknown vs. RT, hazard ratio\u2009=\u20092.898, p\u2009=\u20090.034). However, in patients aged 18-39 years, this impact was not significant. Omission of RT in selected young patients may be considered.